|
1
|
Balogh L, Oláh K, Sánta S, Majerhoffer N
and Németh T: Novel and potential future therapeutic options in
systemic autoimmune diseases. Front Immunol.
15(1249500)2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Tian J, Zhang D, Yao X, Huang Y and Lu Q:
Global epidemiology of systemic lupus erythematosus: A
comprehensive systematic analysis and modelling study. Ann Rheum
Dis. 82:351–356. 2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wang YF, Zhang Y, Lin Z, Zhang H, Wang TY,
Cao Y, Morris DL, Sheng Y, Yin X, Zhong SL, et al: Identification
of 38 novel loci for systemic lupus erythematosus and genetic
heterogeneity between ancestral groups. Nat Commun.
12(772)2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Xiang K, Wang P, Xu Z, Hu YQ, He YS, Chen
Y, Feng YT, Yin KJ, Huang JX, Wang J, et al: Causal effects of gut
microbiome on systemic lupus erythematosus: A two-sample mendelian
randomization study. Front Immunol. 12(667097)2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zhang Y, Zhao C, Lei Y, Li Q, Jin H and Lu
Q: Development of a predictive model for systemic lupus
erythematosus incidence risk based on environmental exposure
factors. Lupus Sci Med. 11(e001311)2024.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Su X, Yu H, Lei Q, Chen X, Tong Y, Zhang
Z, Yang W, Guo Y and Lin L: Systemic lupus erythematosus:
Pathogenesis and targeted therapy. Mol Biomed. 5(54)2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wang M, Zhou J, Niu Q and Wang H:
Mechanism of tacrolimus in the treatment of lupus nephritis. Front
Pharmacol. 15(1331800)2024.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bai W, Li M, Zhou S, Peng L, Zhao J, Tian
X, Wang Q, Leng X, Zhang S, Wang Y, et al: Clinical efficacy of
tacrolimus in systemic lupus erythematosus with various
manifestations: A real-world study. Chin Med J (Engl).
135:2245–2247. 2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Li M, Zhao Y, Zhang Z, Huang C, Liu Y, Gu
J, Zhang X, Xu H, Li X, Wu L, et al: 2020 Chinese guidelines for
the diagnosis and treatment of systemic lupus erythematosus.
Rheumatol Immunol Res. 1:5–23. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Higgins JP, Altman DG, Gøtzsche PC, Jüni
P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et
al: The cochrane Collaboration's tool for assessing risk of bias in
randomised trials. BMJ. 343(d5928)2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Stang A: Critical evaluation of the
Newcastle-Ottawa scale for the assessment of the quality of
nonrandomized studies in meta-analyses. Eur J Epidemiol.
25:603–605. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Szeto CC, Kwan BC, Lai FM, Tam LS, Li EK,
Chow KM, Gang W and Li PK: Tacrolimus for the treatment of systemic
lupus erythematosus with pure class V nephritis. Rheumatology
(Oxford). 47:1678–1681. 2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Chen W, Tang X, Liu Q, Chen W, Fu P, Liu
F, Liao Y, Yang Z, Zhang J, Chen J, et al: Short-term outcomes of
induction therapy with tacrolimus versus cyclophosphamide for
active lupus nephritis: A multicenter randomized clinical trial. Am
J Kidney Dis. 57:235–244. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Chen W, Liu Q, Chen W, Tang X, Fu P, Liu
F, Liao Y, Yang Z, Zhang J, Chen J, et al: Outcomes of maintenance
therapy with tacrolimus versus azathioprine for active lupus
nephritis: A multicenter randomized clinical trial. Lupus.
21:944–952. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang S, Li X, Qu L, Wang R, Chen Y, Li Q,
He X, Zhang X, Wang H, Wu J, et al: Tacrolimus versus
cyclophosphamide as treatment for diffuse proliferative or
membranous lupus nephritis: A non-randomized prospective cohort
study. Lupus. 21:1025–1035. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yap DY, Yu X, Chen XM, Lu F, Chen N, Li
XW, Tang CS and Chan TM: Pilot 24 month study to compare
mycophenolate mofetil and tacrolimus in the treatment of membranous
lupus nephritis with nephrotic syndrome. Nephrology (Carlton).
17:352–357. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y,
Shen P and Chen N: Mycophenolate mofetil or tacrolimus compared
with intravenous cyclophosphamide in the induction treatment for
active lupus nephritis. Nephrol Dial Transplant. 27:1467–1472.
2012.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Mok CC, Ying KY, Yim CW, Siu YP, Tong KH,
To CH and Ng WL: Tacrolimus versus mycophenolate mofetil for
induction therapy of lupus nephritis: A randomised controlled trial
and long-term follow-up. Ann Rheum Dis. 75:30–36. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kamanamool N, Ingsathit A, Rattanasiri S,
Ngamjanyaporn P, Kasitanont N, Chawanasuntorapoj R, Pichaiwong W,
Anutrakulchai S, Sangthawan P, Ophascharoensuk V, et al: Comparison
of disease activity between tacrolimus and mycophenolate mofetil in
lupus nephritis: A randomized controlled trial. Lupus. 27:647–656.
2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhang X, Liu P and Zhang Z: Analysis of
the clinical effects of the combination of mycophenolate mofetil
with either tacrolimus or cyclophosphamide. Clinics (Sao Paulo).
75(e1820)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zheng Z, Zhang H, Peng X, Zhang C, Xing C,
Xu G, Fu P, Ni Z, Chen J, Xu Z, et al: Effect of tacrolimus vs
intravenous cyclophosphamide on complete or partial response in
patients with lupus nephritis: A randomized clinical trial. JAMA
Netw Open. 5(e224492)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhang Q, Xing P, Ren H, Chen X, Xie J,
Zhang W, Shen P, Li X and Chen N: Mycophenolate mofetil or
tacrolimus compared with azathioprine in long-term maintenance
treatment for active lupus nephritis. Front Med. 16:799–807.
2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Suzuki S, Otani T, Ikeda K, Tamura N and
Morimoto S: Additional benefits of belimumab in chronic phase of
systemic lupus erythematosus and efficacy of tacrolimus combination
therapy. Immunol Med. 27:1–7. 2024.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Almaani S, Meara A and Rovin BH: Update on
lupus nephritis. Clin J Am Soc Nephrol. 12:825–835. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Deng J and Xie H, Zhu L, Luo L and Xie H:
Maintenance therapy for lupus nephritis with mycophenolate mofetil
or azathioprine. A meta-analysis. Clin Nephrol. 91:172–179.
2019.PubMed/NCBI View
Article : Google Scholar
|
|
26
|
Prasad N, Kurian J, Agarwal V, Bhadauria
D, Behera M, Yacha M, Kushwaha R, Agrawal V, Jain M and Gupta A:
Long-term outcomes of lupus nephritis treated with regimens based
on cyclophosphamide and mycophenolate mofetil. Lupus. 29:845–853.
2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Suzuki K, Kameda H, Amano K, Nagasawa H,
Takei H, Nishi E, Okuyama A, Tsuzaka K and Takeuchi T: Single
center prospective study of tacrolimus efficacy and safety in the
treatment of various manifestations in systemic lupus
erythematosus. Rheumatol Int. 31:757–763. 2011.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Takahashi S, Hiromura K, Sakurai N,
Matsumoto T, Ikeuchi H, Maeshima A, Kaneko Y, Kuroiwa T and Nojima
Y: Efficacy and safety of tacrolimus for induction therapy in
patients with active lupus nephritis. Mod Rheumatol. 21:282–289.
2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Yap DY, Ma MK, Mok MM, Kwan LP, Chan GC
and Chan TM: Long-term data on tacrolimus treatment in lupus
nephritis. Rheumatology (Oxford). 53:2232–2237. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tanaka H, Watanabe S, Aizawa-Yashiro T,
Oki E, Kumagai N, Tsuruga K and Ito E: Long-term tacrolimus-based
immunosuppressive treatment for young patients with lupus
nephritis: A prospective study in daily clinical practice. Nephron
Clin Pract. 121:C165–C173. 2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Edavalath S, Rai MK, Gupta V, Mishra R,
Misra DP, Gupta L and Agarwal V: Tacrolimus induces remission in
refractory and relapsing lupus nephritis by decreasing
P-glycoprotein expression and function on peripheral blood
lymphocytes. Rheumatol Int. 42:1347–1354. 2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Hiramatsu Y, Yoshida S, Kotani T, Nakamura
E, Kimura Y, Fujita D, Nagayasu Y, Shabana K, Makino S, Takeuchi T
and Arawaka S: Changes in the blood level, efficacy, and safety of
tacrolimus in pregnancy and the lactation period in patients with
systemic lupus erythematosus. Lupus. 27:2245–2252. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Tanaka H, Aizawa T and Endo M: Long-term
outcome of tacrolimus-based immunosuppressive treatment for
patients with paediatric-onset lupus nephritis. Nephrology
(Carlton). 29:901–908. 2024.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Li K, Yu Y, Gao Y, Zhao F, Liang Z and Gao
J: Comparative effectiveness of rituximab and common induction
therapies for lupus nephritis: A systematic review and network
meta-analysis. Front Immunol. 13(859380)2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Shin JI, Li H, Park S, Yang JW, Lee KH, Jo
Y, Park S, Oh J, Kim H, An HJ, et al: Induction and maintenance
treatment of lupus nephritis: A comprehensive review of
meta-analyses. J Clin Med. 11(343)2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lee YH and Song GG: Efficacy and safety of
tacrolimus versus mycophenolate mofetil as induction treatment and
low-dose tacrolimus as treatment for lupus nephritis: A
meta-analysis. Z Rheumatol. 82:754–762. 2023.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Dong Y, Shi J, Wang S, Liu Y, Yu S and
Zhao L: The efficacy of immunosuppressive drugs induction therapy
for lupus nephritis: A systematic review and network meta-analysis.
Ren Fail. 45(2290365)2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Jiang N, Jin S, Yu C, Zhao J, Wang Q, Tian
X, Li M and Zeng X: Efficacy and safety of immunosuppressive agents
for adults with lupus nephritis: A systematic review and network
meta-analysis. Front Immunol. 14(1232244)2023.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Guo Q, Zhang X, Sun S, Tang X, Shen W,
Liang J, Yao G, Geng L, Ding S, Chen H, et al: Association between
mycophenolate mofetil use and subsequent infections among
hospitalized patients with systemic lupus erythematosus: A nested
case-control study. Rheumatol Ther. 10:1535–1554. 2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Yoon KH: Efficacy and cytokine modulating
effects of tacrolimus in systemic lupus erythematosus: A review. J
Biomed Biotechnol. 2010(686480)2010.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Shigesaka M, Ito T, Inaba M, Imai K,
Yamanaka H, Azuma Y, Tanaka A, Amuro H, Nishizawa T, Son Y, et al:
Mycophenolic acid, the active form of mycophenolate mofetil,
interferes with IRF7 nuclear translocation and type I IFN
production by plasmacytoid dendritic cells. Arthritis Res Ther.
22(264)2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Hussenbocus YAAM, Jin Z, Pan W, Liu L, Wu
M, Hu H, Ding X, Wei H, Zou Y, Qian X, et al: Low dosage use of
cyclophosphamide improves the survival of patients with systemic
lupus erythematosus. Clin Rheumatol. 41:2043–2052. 2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Kraaij T, Bredewold OW, Trompet S,
Huizinga TW, Rabelink TJ, de Craen AJ and Teng YK: TAC-TIC use of
tacrolimus-based regimens in lupus nephritis. Lupus Sci Med.
3(e000169)2016.PubMed/NCBI View Article : Google Scholar
|
